UPDATE 2-US reviewing risks of Roche, Novartis, Biogen drugs

* List covers issues identified from April to Sept 2009

* FDA says listing does not mean drug causes the risk (Adds details on other listed drugs, companies not available, links to reports)

WASHINGTON Feb 17 (Reuters) - U.S. health regulators are reviewing potential risks of medicines from Roche Holding AG (ROG.VX), Novartis AG (NOVN.VX) and other companies.

The Food and Drug Administration said on Wednesday it was probing reports of hearing loss with Novartis cancer drug Gleevec, hypothermia with Roche's flu drug Tamiflu and pericarditis with Biogen Idec (BIIB.O) and Elan Corp's (ELN.I) multiple sclerosis drug Tysabri.

The FDA releases a quarterly list of safety probes to inform the public about early investigations of potential side effects that have been reported. The lists released on Wednesday covered issues identified between April 2009 and September 2009. More than two dozen drugs were listed.

Others included rheumatoid arthritis drugs known as tumor necrosis factor (TNF blockers) for reports of demyelinating neuropathy, a neurological disorder. The FDA did not name specific TNF blockers, but the drug include Amgen (AMGN.O) and Pfizer's (PFE.N) Enbrel, and Abbott Laboratories Inc's (ABT.N) Humira.

Being on the list "does not mean that FDA has identified a causal relationship between the drug and the listed risk," the FDA said.

Officials at the drugmakers had no immediate comment or could not immediately be reached.

The FDA posted the lists here and here. (Reporting by Lisa Richwine; Editing by Tim Dobbyn, Leslie Gevirtz)